CAP256V2LS

BIOLOGICAL2 trials

Sponsors

Gilead Sciences, South African Medical Research Council

Conditions

HIV-1-infectionHIV/AIDS

Phase 1

Active, not recruitingPACTR202205715278722

South African Medical Research CouncilHIV/AIDS

Start: 2022-06-27Target: 48Updated: 2026-01-27

Phase 2

Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women

CompletedNCT05281510

Gilead SciencesHIV-1-infection

Start: 2022-06-09End: 2025-01-16Updated: 2026-01-16

Related Papers

Rational Design and Identification of Highly Selective TLR8 Agonists as Potent HIV-1 Latency Reversal Agents.

2026-02-25

Psychological Impact of Analytical Treatment Interruption on Young Women Enrolled in an HIV Cure-Related Clinical Trial in Durban, South Africa.

2025-12-22

Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial

Nature Communications2025-03-0416 citations

Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection

JCI Insight2025-02-235 citations

Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed, uninfected neonates and infants: study protocol for a phase I trial.

2024-07-201 citations